Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers:

Similar documents
Welcome to the Ministry of Foreign Affairs

L A B O R M A R K E T B R I E F I N G S S E R I E S

Event Sponsorship Opportunities

The Belgian pharmaceutical industry strengthens its leading European position. Belgian pharma figures 2015, in a European perspective

Biopeople at a Glance

Fare clic per modificare lo stile del sottotitolo dello schema THE BIOTECH SECTOR IN ITALY AND LOMBARDY

BIOTECH IN FRANCE. key info in. points

2018 MERCER E X E C U T I V E REMUNERATION GUIDES

Swiss Medtech - Europe Medtech Development Dr. Patrik Frei September 2014 Suzhou

A comparative analysis of seven world leading biotech clusters

The role of patients in clinical research

The UK Life Sciences Industry and the Public Markets, 2016/17. World class science, world class investment opportunities

SAMPLE. Bracco Imaging S.p.A.Market Share Analysis. Bracco Imaging S.p.A. Market Share Analysis GDME0639CDB / Published January 2013

FACT SHEET. A CRA Perspective: The Difference between Medical Device Studies and Pharmaceutical Studies.

Robots. Motion Control. Software. Machine vision. Investment. Controllers. Artificial intelligence. Applications. Grippers.

Investigating Clinical Trial Costs Comparative Analysis of Trial Cost Components in Key Geographies Table of Contents

Consulting Storage Software Services Training. NoCount

Patient Involvement in HTA: An example of How and Why. 26 September 2017

Global Wellness Technology Business - High Potential for Future Success. Pasi Sorvisto

Hannover, your first foothold for business expansion into Europe

Investing in people TALENT ACQUISITION TRAINING AND DEVELOPMENT

Inaugural Fraunhofer Delaware Technology Summit

4 Strategic Directions for Czech Economic Policy

European Pharmaceutical Policy: Access for Patients or Improving Competitiveness

MERCER WEBCAST PRELUDE TO DAVOS A PREVIEW of THE WORLD S HUMAN CAPITAL AGENDA DECEMBER 4, 2013

The Innovative Medicines Initiative

HEALTH WEALTH CAREER MERCER LIFE SCIENCES REMUNERATION SURVEY

2015 MERCER LIFE SCIENCES REMUNERATION SURVEY

The Bio-Health Industry in Denmark

SWEDEN. Life Sciences Trend Analysis 2013

Technology Transfer, Academic and Industry Cooperations

Image Processing. Software. Vision Systems. Accessories. Illumination. Cabling. Optics. Cameras. Computers. Acquisition.

Maximising Malaysia s Role in the Global Biopharmaceutical Value Chain

BUILDING A STRONG EMPLOYER BRAND TO ATTRACT LOCAL TALENT IN INDONESIA PT Anugerah Pharmindo Lestari (PT APL)

Integrated Value-Added Services. Tom Dolan President, Xerox Global Services

PREVIEW. Benchmarking European Investigator Payments Industry Standard Research

The Essential Guide To Managing Biotech Labs

Supported by: Flanders Welcome Team Life Sciences

The Scientist Online. Reach. Segmentation. Technology. MEDIA KIT 2007

EVOTEC REPORTS FIRST QUARTER 2018 RESULTS AND PROVIDES CORPORATE UPDATE

Valuing Healthcare Biotechnology in Europe: EuropaBio s perspective

NEWSFLASH 03. FASILIS update. FASILIS: Stimulating new business development in Human Health

LEO Pharma Commercial Excellence EU+

The European Medical Technology Industry. in figures / 2018

International Conference on Pharmacy and Pharmaceutical Sciences April 09-11, 2018, Dubai UAE

Microsoft Dynamics 365 Business Central. Licensing Guide - Simplified. May 2018

Australia: A Dynamic Environment for Conducting Clinical Trials

MARKET ENTRY SOLUTIONS IN THE WORLD S LARGEST ECONOMY

ehealth-strategien im Wettbewerb: Erfolgsfaktor oder schmückendes Beiwerk? ehealth Kongress Darmstadt, 17 Oktober 2014

Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies

Solution Partner Program Global Perspective

VISION & STRATEGY FIC LIC. Interview with the President

The Globalization of Biotechnology. Alicia Löffler Northwestern University

Jefferies 2018 Global Healthcare Conference. June 7, 2018

EXECUTIVE SEARCH AND RECRUITMENT A SMART SERVICE

Biotech & Pharma. Industries with the most favourable conditions for growth in Lublin

Biosimilar Medicines: Opportunities for Sustainable Healthcare. Opening Address Greg Perry Director General EGA London 3-4 May 2007

EIB Support in Life Sciences. Shiva Dustdar Head of Division, Innovation Finance Advisory European Investment Bank BIO-Europe Berlin, 7 November 2017

BIOSCIENTIA. Good outcomes are based on good values. Central lab services and biomarker analytics for clinical trials

HR Officer/Administrator Ardagh Metal Packaging, Hjørring

EDUCATION POLICY ANALYSIS (Phillip McKenzie, 3 November 2003)

Event Sponsorship Opportunities

Inclusive Growth in Scotland. Gary Gillespie, Chief Economist Scottish Government 12 th February 2016

Exemplary Project. COILED THE NETHERLANDS April 2018

Disclaimer. 2

Global Attraction and Retention Survey

BIOTECH FINANCING SUMMARY October 2016

Well-being in regions: Building more coherent policies for a better growth model

GMP. Safeguard The Patient s Health.

Innovation and Sustainability: An integrated approach

Our software, your success

The Fourth Community Innovation Survey (CIS IV)

Outsourcing in Clinical Trials Nordics October 30 th 31 st Copenhagen

Top Management Reporting Survey Are you realizing the full potential of your management reporting?

EXECUTIVE SUMMARY. Overview of Autoimmune Disease Research

Clinical Trials: Facts and Trends. Dr Nik Nikitin. Founder/Director, Russlan Clinical. ManxBioMed Annual Bio Business Conference 10 th December 2013

COMPENSATION REVIEW AND ANALYSIS SERVICES TAKING THE WORK OUT OF YOUR COMPENSATION REVIEW PROCESS

Modern Slavery Statement

National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy

Intellectual property: The driving force for growth and funding

Our software, your success

EMBARGOED UNTIL 7:38 AM October 31, 2016

A.I.S.E. s 11 th INFORMATION DAY: Cleanliness and Hygiene : Benefits of the Professional Cleaning sector

BioWorld s PARTNER in FOCUS: Open Innovations: Moscow

The world s largest global training provider. theknowledgeacademy.com

2015 Investor Meeting

1.0 Background to the organisation

Time to assess your global mobility programme

CHASING THE NEXT BIOTECH UNICORN HOW THE BIOTECH SECTOR SETS TO THRIVE AMID REGULATORY AND LISTING CHANGES IN CHINA AND HONG KONG

Strategic Overview of the Biotechnology Industry

Working Together for Better Health Partnering with Boehringer Ingelheim. JOURNEE COLLABORATIVE DE LYONBIOPOLE October 10, 2017

Biotechnology Report. Turkey

HEALTH WEALTH CAREER ROTATOR ASSIGNMENTS: TRENDS, CHALLENGES, AND OPPORTUNITIES FOR ENERGY, ENGINEERING & CONSTRUCTION, AND MINING

Jefferies 2017 Global Healthcare Conference. June 7, 2017

COMMERCIAL ATTRACTIVENESS OF BIOMEDICAL R&D IN MEDICON VALLEY. The Role of R&D in Attracting Regional Investments. November 2002

Commercialising early stage agbiotechnology from academia: challenges and opportunities. Rupert Osborn CEO, IP Pragmatics Ltd March 2011

CONTRACTING CELL CULTURE

European bioregions : strengths and partnership strategies. The bioxclusters example BioPartnering Latin America cluster forum september 2013

Career Growth Areas in Physiology / Pharmacology

Transcription:

MEDICON VALLEY / 2011 03 Develop YOUR business in Medicon Valley Dedicated to helping you develop your business, Medicon Valley offers: > A pool of highly qualified life-science university graduates and workers > Effective technology transfer from universities to companies > Opportunities to partner with mature pharma, biotech and medtech companies > A rich source of opportunity for venture capitalists interested in attractive life science companies > An abundance of new licensing opportunities > An outstanding environment, ideal for conducting clinical trials Addressing unmet medical needs Medicon Valley plays host to companies addressing large, unmet medical needs with groundbreaking research into oncology, diabetes, CNS, inflammation, immunology, personalised medicine and infectious diseases. Thriving on synergies between life science companies, hospitals, universities and research institutions, your business could be part of a dynamic environment rich in innovation and knowledge-sharing. How Copenhagen Capacity and Invest In Skåne can help your company Free of charge, our teams of dedicated life science specialists can: > Save you time and money when finding the right partners and investment opportunities > Run a benchmark analysis to compare the cost and quality of Medicon Valley with locations around the world > Act as your personal guide in Medicon Valley to make sure you meet the right people and companies > Take care of the practicalities while you focus on what matters most your business Medicon Valley in numbers: > Biotech and pharma companies: > 150 > Medtech companies: > 200 > Employees in the private life science sector: 44,000 > Universities : 11, of which 5 offer life science degree courses > Students: 155,000 > Life science students: 45,000 > New life science graduates each year: 9,000 > Hospitals: 33, of which 11 are University hospitals > Science parks with a focus on life science: 9 > Contract research organisations and contract manufacturing organisations: 50+

04 MEDICON VALLEY / 2011 THE PLACE TO DEVELOP YOUR BUSINESS One of Europe s top three pharma, biotech and medtech clusters, Medicon Valley offers a healthy business environment with opportunities for extensive collaboration and synergies between life science companies, academic research centres and clinicians. Finance your growth in Medicon Valley The majority of biotech companies in Medicon Valley emerged in the mid-1990s. Since then, most of them have succeeded in getting their compounds into clinical development (see graph on next page), giving Medicon Valley one of the strongest biotech pipelines in Europe. With more than a dozen active venture capitalists (VCs) specialising in life science in the region, venture capital financing is extremely stable. Typically, a Nordic VC will act as a lead investor in Medicon Valley and syndicate investments with international or other Nordic VCs. As the region s overall clinical pipeline matures, international investors will play a key role. Thanks to a high concentration of biotech companies with lead candidates in the late stages of clinical development, Medicon Valley offers attractive business opportunities for pharmaceutical companies and financial investors. Invest in Skåne and Copenhagen Capacity have a long track record of helping investors select companies and business opportunities that meet their strategic goals and we can do the same for you. Strategic alliance When it comes to tapping into the business opportunities in Medicon Valley, your company has many options. One is to establish a strategic alliance with one of the 350 biotech and medtech companies.

MEDICON VALLEY / 2011 05 With close ties to local companies in Medicon Valley, Copenhagen Capacity and Invest in Skåne are perfectly positioned to help you identify potential business partners. Every year, we help many international companies secure win-win agreements with companies in Medicon Valley. Read more at www.mediconvalley.com To see the latest opportunities at Medicon Valley as they arise, sign up for our monthly newsletter. Simply go to www.mediconvalley.com/subscribe An impressive pipeline In just ten years, Medicon Valley has become an established life science cluster with a diverse pipeline of promising lead candidates. NUMBER OF PRODUCT CANDIDATES PHASE 1 PHASE 2 PHASE 3 UNITED KINGDOM GERMANY DENMARK FRANCE SWITZERLAND SWEDEN ISRAEL ITALY NETHERLANDS NORWAY SPAIN IRELAND BELGIUM AUSTRIA FINLAND 0 50 100 150 200 250 SOURCE: Ernst & Young / Beyond borders 2011 (figures are for 2010) Minimise your administrative costs Medicon Valley is a business-friendly region. Corporate tax rates are low in comparison with other mature economies in (western) Europe, moreover efficient government procedures enable your company to reduce administrative costs. This means you can allocate more resources to your business. In Medicon Valley, public authorities work with companies. Anna Williamson Senior Manager, Business Development, Genentech The Medicon Valley has a well-established life sciences community with recognized strengths in drug discovery, development, diagnostics and medical devices. Genentech has a number of collaborations with top companies in the area and we continue to regard it as a high-potential region for sourcing business opportunities.

COPYRIGHT COPENHAGEN CAPACITY / INVEST IN SKÅNE

08 MEDICON VALLEY / 2011 HIGHLY EDUCATED WORKFORCE Your company s most valuable asset is your staff. In Medicon Valley, you have immediate access to talented people who can become the world-class workforce you need to grow your business. MANAGEMENT EXPERTISE In the last decade, more than a hundred biotech start-ups have settled in Medicon Valley. Now mature, many of them are in latestage clinical development and preparing to partner or launch their lead candidates. After initial rounds of funding by venture capitalists, some Medicon Valley companies have listed on the Nordic OMX or other stock exchanges. This shows the commitment and determination of local biotech executives who have what it takes to transform innovative start-ups into successful companies. RESEARCHERS AND LIFE SCIENCE SPECIALISTS About 44,000 people are employed in the private life science sector in Medicon Valley, and many of them work in R&D. The cluster is home to internationally renowned pharma, biotech diagnostics and medtech companies, such as ArjoHuntleigh, Gambro, Novo Nordisk, H. Lundbeck, Leo Pharma, DAKO, Coloplast and Ambu. Medicon Valley plays host to 350 biotechnology and medtech companies and offers all the skills and expertise you need to carry out demanding life science R&D. More than 50 companies can offer you support in the form of preclinical or clinical development, IP consulting, and contract manufacturing. ACADEMIC RESOURCES Scandinavian countries are very focused on education. As a percentage of GDP, public spending on education is one of the highest in the world (according to IMD, World Competitiveness Year book, 2010). Not surprisingly, Medicon Valley is home to some prestigious universities, such as The Danish Technical University, Copenhagen University and Lund University all internationally recognised for their advanced research facilities and outstanding achievements. Medicon Valley s 11 universities guarantee a steady supply of highly qualified young people. And many of them will graduate with a degree directly relevant to life science.

MEDICON VALLEY / 2011 09 David H Solomon President, Chief Executive Officer, Zealand Pharma In order for a biopharmaceutical company like Zealand Pharma to continue its success and to create value, it is of utmost importance to have access to a pool of highly skilled and talented scientists as well as senior managers with relevant business experience and an insightful understanding of the sector. All this we find in the well-established and thriving environment of the Medicon Valley region.

10 MEDICON VALLEY / 2011 A PERFECT WORK/ LIFE BALANCE In Medicon Valley, combining work and family life is easy and highly appealing to expatriates. Companies offer flexible working hours so you can balance a successful career with a rich, fulfilling family life. AN ATTRACTIVE PLACE TO LIVE Free schools, free healthcare, easy access to childcare, a safe, healthy environment with a low crime rate and good leisure facilities these are just some of the benefits of living and working in Medicon Valley. With a rich heritage and modern facilities, the region s principal cities, Copenhagen and Malmö, offer unique cultural experiences and plenty of opportunities for outdoor activities. What s more, forests and beaches are never more than half an hour s drive away. International, trendsetting magazine Monocle recently declared Copenhagen the world s second most attractive city to live in. Monocle s 2010 survey, which assessed 40 major cities on criteria such as public transport, education, ease of doing business and hours of sunshine, commended Copenhagen for its compact town planning, good regional transport network and clean, safe environment.